Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

belgische technische gassen - gaz technique belgique s.p.r.l.-b.v.b.a. - oxygen 100 % v/v - medicinal gas, compressed - oxygen

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

belgische technische gassen - gaz technique belgique s.p.r.l.-b.v.b.a. - oxygen 100 % - medicinal gas, compressed - oxygen

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

belgische technische gassen - gaz technique belgique s.p.r.l.-b.v.b.a. - oxygen 100 % v/v - medicinal gas, cryogenic - oxygen

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

oxycure sa-nv - oxygen 100 % v/v - medicinal gas, compressed - oxygen

Malta - English - Medicines Authority

poligas limited hal-farrug road, luqa, lqa 05, malta - oxygen - inhalation gas - oxygen 99.5 % (v/v) - all other therapeutic products

European Union - English - EMA (European Medicines Agency)

pfizer limited  - metaflumizone - ectoparasiticides for topical use, incl. insecticides - cats - treatment and prevention of flea infestations (ctenocephalides canis and c. felis) in cats. the veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (fad).

European Union - English - EMA (European Medicines Agency)

pfizer limited  - metaflumizone, amitraz - ectoparasiticides for topical use, incl. insecticides - dogs - for the treatment and prevention of infestations by fleas (ctenocephalides canis and c. felis), and ticks (ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus, dermacentor reticulatus and dermacentor variabilis), and treatment of demodicosis (caused by demodex spp.) and lice (trichodectes canis) in dogs.the veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (fad).

European Union - English - EMA (European Medicines Agency)

cis bio international - depreotide trifluoroacetate - radionuclide imaging - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.for scintigraphic imaging of suspected malignant tumours in the lung after initial detection, incombination with ct scan or chest x-ray, in patients with solitary pulmonary nodules.

European Union - English - EMA (European Medicines Agency)

schering-plough europe - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - posaconazole sp is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole sp is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

European Union - English - EMA (European Medicines Agency)

ge healthcare as - mangafodipir trisodium - magnetic resonance imaging - contrast media - this medicinal product is for diagnostic use only.contrast medium for diagnostic magnetic resonance imaging (mri) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas. as an adjunct to mri to aid in the investigation of focal pancreatic lesions.